November 12th, 2020 – On October 27, 2020, the Alliance for Aging Research’s Michael Ward provided public comment to the U.S. Food and Drug Administration (FDA) at the first public meeting for the Medical Device User Fee Amendments (MDUFA) reauthorization for Fiscal Years 2023 through 2027. In his comments, Michael emphasized the importance of:
- FDA investment to support review and surveillance of digital health technologies;
- Increasing patient access to device labeling and benefit-risk statements;
- Appropriate access to publicly-reported data to patient device registries
- Partnering with the Patient-Centered Outcomes Research Institute to develop real-world evidence on device safety and efficacy.
Read the full comment or watch the video here.
About the Alliance for Aging Research
The Alliance for Aging Research is the leading nonprofit organization dedicated to accelerating the pace of scientific discoveries and their application to vastly improve the universal human experience of aging and health. The Alliance believes advances in research help people live longer, happier, more productive lives and reduce healthcare costs over the long term. For more than 30 years, the Alliance has guided efforts to substantially increase funding and focus for aging at the National Institutes of Health and Food and Drug Administration; built influential coalitions to guide groundbreaking regulatory improvements for age-related diseases; and created award-winning, high-impact educational materials to improve the health and well-being of older adults and their family caregivers. For more information, visit www.agingresearch.org